Celiac Disease - NIH Consensus Development Program - National ...

More documents

Recommendations

Info

Tuesday, June 29, 2004 (continued)IV. Who Should Be Tested for Celiac Disease? (continued)9:10 a.m. Evidence-Based Practice Center Presentation: Consequences of Testingfor Celiac DiseaseAnn Cranney, M.D., M.Sc.Associate Professor Clinical Epidemiology Program Ottawa Health Research InstituteCivic Hospital Site9:30 a.m. DiscussionV. What Is the Management of Celiac Disease?10:00 a.m. Dietary Guidelines for Celiac Disease and ImplementationCynthia Kupper, R.D., C.D.Executive DirectorGluten Intolerance Group of North America 10:20 a.m. How To Provide Effective Education and Resources: Gluten-Free DietsShelley Case, R.D.Case Nutrition Consulting10:40 a.m. The Followup of Patients With Celiac Disease⎯Achieving ComplianceWith TreatmentMichelle Maria Pietzak, M.D.Director, Center for Celiac Research–WestChildrens Hospital Los Angeles Assistant Professor of Pediatrics University of Southern California Keck School of Medicine 11:00 a.m. Discussion11:30 a.m. AdjournmentWednesday, June 30, 20049:00 a.m. Presentation of the Consensus Statement9:30 a.m. Public DiscussionThe panel chair will call for questions and comments from the audience on thedraft consensus statement, beginning with the introduction and continuingthrough each subsequent section in turn. Please confine your comments to thesection under discussion. The chair will use discretion in proceeding tosubsequent sessions so that comments on the entire statement may be heardduring the time allotted. Comments cannot be accepted after 11:30 a.m.7
Wednesday, June 30, 2004 (continued)11:00 a.m. Conference AdjournsPanel meets in executive session to review public comment. Conferenceparticipants are welcome to return to the main auditorium to attend the pressconference at 2:00 p.m.; however, only members of the media are permitted to askquestions during the press conference.2:00 p.m. Press ConferenceThe panel’s draft statement will be posted to consensus.nih.gov as soon as possible after theclose of proceedings, and the final statement will be posted 3 to 4 weeks later.8
Page 1 and 2: NIH Consensus Development Conferenc
Page 3 and 4: III. What Are the Manifestations an
Page 5 and 6: • What is the management of celia
Page 7 and 8: Monday, June 28, 2004 (continued)I.
Page 9: Monday, June 28, 2004 (continued)II
Page 13 and 14: Lisa H. RichardsonConsumer Represen
Page 15 and 16: Ciaran P. Kelly, M.D.Director, Celi
Page 17 and 18: Van S. Hubbard, M.D., Ph.D.Director
Page 19 and 20: AbstractsThe following are abstract
Page 21 and 22: susceptibility (e.g., DR17 homozygo
Page 23 and 24: The Pathology of Celiac DiseaseDavi
Page 25 and 26: In this regard, the transport pathw
Page 27 and 28: for the IgG-based test, while speci
Page 29 and 30: 15. de Lecea A, Ribes-Koninckx C, P
Page 31 and 32: Clinical Algorithm in Celiac Diseas
Page 33 and 34: Considera diagnosisof celiac diseas
Page 35 and 36: There are populations at particular
Page 37 and 38: Serological Testing for Celiac Dise
Page 39 and 40: Estimates of the sensitivity of the
Page 41 and 42: the risk and severity of CD may als
Page 43 and 44: What Are the Prevalence and Inciden
Page 45 and 46: ascribed to excess menstrual loss.
Page 47 and 48: ReferencesFamily History of Celiac
Page 49 and 50: Carroccio A, Iannitto E, Cavataio F
Page 51 and 52: identified by surveys or through so
Page 53 and 54: Clinical Presentation of Celiac Dis
Page 55 and 56: een widely reported. The question r
Page 57 and 58: The Many Faces of Celiac Disease: C
Page 59 and 60: References1. Green PH, Jabri B. Coe
Page 61 and 62:
Association of Celiac Disease and G
Page 63 and 64:
Does the Gluten-Free Diet Protect F
Page 65 and 66:
Skin Manifestations of Celiac Disea
Page 67 and 68:
allow a better understanding of the
Page 69 and 70:
4. Henriksson KG, Hallert C, Walan
Page 71 and 72:
characterized, clinically-identifie
Page 73 and 74:
10. Hoffenberg EJ, Emery LM, Barrig
Page 75 and 76:
ataxia, epilepsy with posterior cer
Page 77 and 78:
Consequences of Testing for Celiac
Page 79 and 80:
Osteoporosis/FracturesThere were 11
Page 81 and 82:
Dietary Guidelines for Celiac Disea
Page 85 and 86:
21. Thompson T. Thiamin, riboflavin
Page 88 and 89:
In order to effectively counsel ind
Page 90 and 91:
9. Hallert C, Granno C, Hulten S, M
Page 92 and 93:
adhered to the GFD after more than
Page 94 and 95:
Patient education, close supervisio
Page 96:
26. Mustalahti K, Lohiniemi S, Laip
show all

Celiac Disease - NIH Consensus Development Program - National ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?